InvestorsHub Logo
Followers 2
Posts 696
Boards Moderated 0
Alias Born 03/07/2018

Re: None

Thursday, 02/21/2019 11:20:54 AM

Thursday, February 21, 2019 11:20:54 AM

Post# of 32923
OMG HUGE news! https://ih.advfn.com/stock-market/USOTC/kali-inc-KALY/stock-news/79318158/kaly-kali-extracts-inc-previews-pending-report

The primate study was conducted by Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and his Biomedical Science Research Group (BSRG). Professor Osbourn made the following statement in regard to the research adding to his original statement published on February 5th, 2019:

“We investigated the effects of a novel, new agent for the oral treatment of lung diseases like inflammation of the lung airways in nonhuman primates with chronic pulmonary fibrosis. The new NCM Biotech supplement was evaluated at 3 separate concentrations and compared to placebo treated animals. After only 2 weeks of daily oral treatment, a 5 fold dilution of the supplement extract increased respiration rate by 55%, airway flow rate by 82%, inspiratory airway flow velocity by 149%, and tidal volume by 38% compared to each animal’s own control values. Blood pressure and heart rate were not changed by the compound during this time frame. These large increases in pulmonary function in fibrotic lungs elicited marked increases in resting minute ventilation in these animals. A full report of the detailed data will be available within the next 2 weeks.